Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist.
In this work, we developed a new prolactin receptor (PRLR) antagonist using the hybridoma technique. A series of monoclonal antibodies against prolactin receptor (PRLR) was prepared, from which we characterized and selected one anti-PRLR antibody, F56. Epitome mapping showed that F56 and prolactin (PRL) share a common binding epitope on PRLR, and therefore, F56 could compete with prolactin (PRL) for binding to PRLR. Subsequent experiments indicated that F56 could effectively neutralize PRLR-mediated intracellular signalling molecules, such as signal transducer and activator of transcription (STAT) and extracellular signal-regulated kinase-1 and kinase 2 (ERK1/2), either by endogenously expressed PRLR or in a cell model transfected with PRLR. In addition, further experiments showed that F56 could effectively inhibit PRL-induced cell proliferation. The current study suggests that F56 has potential applications in PRLR-related studies.
College of Animal Science and Technology Jilin Agricultural University, Changchun, Jilin Xincheng street 2888, Changchun 130118, PR China. Electronic address: chzh@jlau.edu.cn.
Huanzhong
H
Cui
College of Animal Science and Veterinary Medicine, Jilin University, PR China.
Yun Zhi
YZ
Ma
Henan University of Science and Technology, Xinxiang, Henan province, 471023, PR China.
Yanrong
Y
Wang
College of Animal Science and Technology Jilin Agricultural University, Changchun, Jilin Xincheng street 2888, Changchun 130118, PR China.
Meng
M
Song
College of Animal Science and Technology Jilin Agricultural University, Changchun, Jilin Xincheng street 2888, Changchun 130118, PR China.
Hui
H
Zhang
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000302:isolation & purification / Q000494:pharmacology; D001667:Binding, Competitive; D016466:CHO Cells; D049109:Cell Proliferation; D003412:Cricetulus; D018604:Epitope Mapping; D000939:Epitopes / Q000737:chemistry* / Q000276:immunology; D005786:Gene Expression Regulation; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D051379:Mice; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000276:immunology; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000276:immunology; D011388:Prolactin / Q000378:metabolism; D011485:Protein Binding; D011981:Receptors, Prolactin / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D050791:STAT Transcription Factors / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction; D014162:Transfection
D000911:Antibodies, Monoclonal; D000939:Epitopes; D011981:Receptors, Prolactin; D050791:STAT Transcription Factors; D011388:Prolactin; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
Antagonist; Antibody; PRLR; Prolactin; Signalling protein